Table 1.
Demographic and baseline disease characteristics
| Characteristic | N = 70 |
|---|---|
| Sex, n (%) | |
| Male | 40 (57.1) |
| Female | 30 (42.9) |
| Race, n (%) | |
| Chinese | 70 (100) |
| Age, years | |
| Median (range) | 32.5 (18–69) |
| ≥65 years, n (%) | 4 (5.7) |
| ECOG performance status, n (%) | |
| 0 | 48 (68.6) |
| 1 | 22 (31.4) |
| Median time from initial diagnosis, months | 25.3 |
| Advanced diseasea, n (%) | 60 (85.7) |
| Histologic subtype, n (%) | |
| Nodular sclerosis | 42 (60) |
| Mixed cellularity | 19 (27.1) |
| Lymphocyte rich | 3 (4.3) |
| Unspecified | 6 (8.6) |
| Bulky diseaseb, n (%) | 8 (11.4) |
| Bone marrow involvement, n (%) | 22 (31.4) |
| B-symptom(s), n (%) | 26 (37.1) |
| Median (range) lines of prior therapy | 3 (2–11) |
| Types of prior systemic therapy, n (%) | |
| Chemotherapy | 70 (100) |
| ASCT | 13 (18.6) |
| Immunotherapyc | 15 (21.4) |
| Ineligible for prior ASCTd, n (%) | 57 (81.4) |
| Patients with prior radiation therapy, n (%) | 21 (30.0) |
| Refractory diseasee, n (%) | 45 (52.3) |
aAdvanced disease is defined as Ann Arbor Stage IIB, IIIA or B, Stage IIIE A or B, and Stage IV A or B
bBulky disease defined as mediastinal mass ratio of 0.33 or size of any single node/nodal mass ≥ 10 cm in diameter
cImmunotherapy included brentuximab vedotin, rituximab, cytokine-induced killer cell transfusion, thalidomide, or lenalidomide
dPatients were ineligible for ASCT if they did not achieve at least a partial response to salvage chemotherapy, were ≥65 years of age, had contraindicating comorbidities, or due to the failure or inability to collect hematopoietic stem cells. All received ≥2 prior regimens
eRefractory disease was defined as the lack of at least a partial response to the last therapy before study entry, as assessed by the investigator